Pharmaceutical Manufacturing & Supply – Erythromycin Ophthalmic Ointment

The contract requires the manufacture and supply of FDA-compliant Erythromycin Ophthalmic Ointment to meet strict specifications set by the Defense Logistics Agency, including adherence to the Berry Amendment and the Buy American Act, ensuring all materials and production originate in the United States. The product must fulfill rigorous pharmaceutical standards for safety, potency, and sterility as required for military medical use, with delivery targeted to Fort Bragg, North Carolina, 28310. The solicitation is issued as a subcontract under the Department of Defense’s Medical Supply Chain Pharm FSA, with a NAICS code of 325412 indicating pharmaceutical preparation manufacturing. Proposals must be submitted by July 20, 2026, following the posting date of July 12, 2026, and bidders must demonstrate full compliance with U.S. origin requirements for all components and manufacturing processes. The contract is tied to critical defense medical supply chains, emphasizing domestic production to support the operational readiness of U.S. armed forces. Failure to meet FDA, Berry Amendment, or Buy American Act provisions will result in disqualification. All activities must align with the DLA’s procurement protocols, and the submission must be made through the DIBBS platform using the referenced solicitation link.